Replies to post #164205 on Biotech Values

[cooldrinkh2o]

My guess is transplant sales growth is relatively flat. Certican in some EU countries is being used in oncology indications due the large price difference (10 1 mg Certican tablets cost is much lower than 1 10mg Afinitor tablet in all/most EU countries). I would still submit that most of the growth in sales is due to the ER+ BC launch.

[cooldrinkh2o]

Biased because I worked on the global launch plan in 11/12 (as did a large number of internal NVS and external agency/vendors).